



Karolin Behringer

Contact

Karolin Behringer

Publications (3)

Kreissl S, Borchmann P, Engert A, Diehl V, Fuchs M, Flechtner H, Rueffer J, Shonukan O, Soekler M, Hitz F, Halbsguth T, Behringer K, Brillant C, Mayer A, Goergen H, Mueller H. Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group. *Lancet Oncol* 2016; 17:1453-1462.

Böll B, Engert A, Diehl V, Fuchs M, Borchmann S, Bürkle C, Eichenauer D, von Tresckow B, Greil R, Kerkhoff A, Hitz F, Bröckelmann P, Behringer K, Goergen H, Borchmann P. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. *Blood* 2016; 127:2189-92.

Behringer K, Lange E, Mahlberg R, Hassler A, Vogelhuber M, Hahn D, Mezger J, Krause S, Skoetz N, Böll B, von Tresckow B, Diehl V, Hallek M, Borchmann P, Stein H, Eich H, Engert A, Bentz M, Vieler T, Kriz J, Goergen H, Tanner A, Zijlstra J, Greil R, Markova J, Sasse S, Fuchs M, Topp M, Soekler M, Mathas S, Meissner J, Wilhelm M, Koch P, Lindemann H, Schalk E, Semrau R. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. *Lancet* 2014; 385:1418-27.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch